<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101074</url>
  </required_header>
  <id_info>
    <org_study_id>V111_05</org_study_id>
    <nct_id>NCT01101074</nct_id>
  </id_info>
  <brief_title>Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine</brief_title>
  <official_title>A Prospective Observational Study of Safety and Effectiveness Following Administration of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This observational study will evaluate the safety and effectiveness following administration
      of adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine through both an ad
      hoc active monitoring system and a passive surveillance of hospitalization in a large cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Flu Egg Derived Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine by estimating the incidence of reported Adverse Events, Serious Adverse Events or Adverse Events of Special Interest in a cohort of actively monitored vaccinated subjects</measure>
    <time_frame>Within 3 weeks and 6 weeks after vaccine administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of hospitalization within 6 weeks and 2 years after vaccination in a cohort of subjects vaccinated sw unvaccinated subjects, with Flu Egg Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">135469</enrollment>
  <condition>Influenza A (H1N1)</condition>
  <arm_group>
    <arm_group_label>6-23 months</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2-8 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>9-17 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>18-44 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>45-60 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;60 years</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>This is non-intervention observational study</intervention_name>
    <description>This is non-intervention observational study</description>
    <arm_group_label>6-23 months</arm_group_label>
    <arm_group_label>2-8 years</arm_group_label>
    <arm_group_label>9-17 years</arm_group_label>
    <arm_group_label>18-44 years</arm_group_label>
    <arm_group_label>45-60 years</arm_group_label>
    <arm_group_label>&gt;60 years</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population of children, adolescents, adults and elderly
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects resident in Emilia-Romagna and either registered with the AUSL of Reggio
             Emilia, Bologna, Modena and Parma or working in the province of Reggio Emilia,
             Bologna, Modena and Parma included in the target groups described in the Study
             Protocol vaccination with H1N1sw vaccine Focetria is recommended - according to the
             national pandemic plan adopted at the local level - will be eligible for enrolment.

        Exclusion Criteria:

          -  Subjects already vaccinated with another pandemic vaccine or with known
             contraindications to Focetria, will be excluded from this study.

          -  Patients institutionalized in Hospital, Nursing Homes, Rehabilitation Centers, as well
             as home-cared patients, will also be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Emilia Romagna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Swine Flu A (H1N1) vaccine</keyword>
  <keyword>Adjuvanted flu egg derived</keyword>
  <keyword>Novel influenza A (H1N1): a new flu virus of swine origin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

